

Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients

NCT07372170

Status RECRUITING
Sponsor Infanta Leonor University Hospital
Enrollment 600 participants

Key Eligibility Criteria

Inclusion (4)

- Adults (≥18 years) with a diagnosis of thrombotic antiphospholipid syndrome.
- Low-risk antiphospholipid syndrome defined by previous venous thrombosis and a single or double positive antiphospholipid antibody profile (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta-2-glycoprotein I antibodies).
- Patients receiving long-term anticoagulant treatment with direct oral anticoagulants or vitamin K antagonists according to routine clinical practice.
- At least 2 weeks of continuous anticoagulant treatment before study inclusion.

Exclusion (4)

- Age <18 years.
- Triple antiphospholipid antibody positivity.
- History of arterial thrombosis.
- Anticoagulation for indications other than secondary prevention of venous thrombosis related to antiphospholipid syndrome.

Locations (2 total)

Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain
Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain